NIKA PHARMACEUTICALS, INC

Nika Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing, and distributing prescription therapies and dietary food supplements. Its primary pharmaceutical assets include Thymus Nuclear Glycoprotein, intended for treating human immunodeficiency virus infections, alongside treatments developed on an inactivated pepsin fraction platform. The company also distributes multiple dietary supplement lines, including Carotilen, Physiolong, Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C, and Silymaron, designed for cellular protection, immune stimulation, and physical convalescence. Its offerings serve individuals undergoing physical recovery as well as patients managing chronic viral conditions.

The enterprise is based in Henderson, Nevada, and does not own any real estate property. Through agreements and an eighty percent controlling stake in its affiliate Nika Europe, the business holds production and representation rights across North America, South America, Europe, Asia, Africa, and Australia. Its European affiliate prepares the development of a specialized manufacturing plant designed to produce pharmaceuticals in tablet, injectable, and alternative formats to fulfill company supply needs.

Summary of the business section of Nika Pharmaceuticals's latest annual report, written by StockData.